Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives

References

• JemalASiegelRXuJWardECancer statistics, 2010CA Cancer J Clin201060527730020610543
   PubMed Web of Science ®Google Scholar
• RappEPaterJLWillanAChemotherapy can prolong survival in patients with advanced non-small-cell lung cancer – report of a Canadian multicenter randomized trialJ Clin Oncol1988646336412833577
   PubMed Web of Science ®Google Scholar
• SchillerJHHarringtonDBelaniCPEastern Cooperative Oncology GroupComparison of four chemotherapy regimens for advanced non-small-cell lung cancerN Engl J Med20023462929811784875
   PubMed Web of Science ®Google Scholar
• WeinsteinIBJoeAKMechanisms of disease: Oncogene addiction – a rationale for molecular targeting in cancer therapyNat Clin Pract Oncol20063844845716894390
   PubMedGoogle Scholar
• GoffinJRZbukKEpidermal growth factor receptor: pathway, therapies, and pipelineClin Ther20133591282130324054705
   PubMed Web of Science ®Google Scholar
• McDermottUSettlemanJPersonalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncologyJ Clin Oncol200927335650565919858389
   PubMed Web of Science ®Google Scholar
• ShepherdFARodrigues PereiraJCiuleanuTNational Cancer Institute of Canada Clinical Trials GroupErlotinib in previously treated non-small-cell lung cancerN Engl J Med2005353212313216014882
   PubMed Web of Science ®Google Scholar
• RosellRCarcerenyEGervaisRSpanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia ToracicaErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialLancet Oncol201213323924622285168
   PubMed Web of Science ®Google Scholar
• MokTSWuYLThongprasertSGefitinib or carboplatin- paclitaxel in pulmonary adenocarcinomaN Engl J Med20093611094795719692680
   PubMed Web of Science ®Google Scholar
• HanJYParkKKimSWFirst-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lungJ Clin Oncol201230101122112822370314
   PubMed Web of Science ®Google Scholar
• ZhouCWuYLChenGErlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyLancet Oncol201112873574221783417
   PubMed Web of Science ®Google Scholar
• GainorJFShawATEmerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancerJ Clin Oncol201331313987399624101047
   PubMed Web of Science ®Google Scholar
• MarteBTumour heterogeneityNature2013501746732724048064
   PubMed Web of Science ®Google Scholar
• BurrellRAMcGranahanNBartekJSwantonCThe causes and consequences of genetic heterogeneity in cancer evolutionNature2013501746733834524048066
   PubMed Web of Science ®Google Scholar
• GovindanRDingLGriffithMGenomic landscape of non-small cell lung cancer in smokers and never-smokersCell201215061121113422980976
   PubMed Web of Science ®Google Scholar
• MeachamCEMorrisonSJTumour heterogeneity and cancer cell plasticityNature2013501746732833724048065
   PubMed Web of Science ®Google Scholar
• ReyaTMorrisonSJClarkeMFWeissmanILStem cells, cancer, and cancer stem cellsNature2001414685910511111689955
   PubMed Web of Science ®Google Scholar
• ShackletonMQuintanaEFearonERMorrisonSJHeterogeneity in cancer: cancer stem cells versus clonal evolutionCell2009138582282919737509
   PubMed Web of Science ®Google Scholar
• SinghSChellappanSLung cancer stem cells: Molecular features and therapeutic targetsMol Aspects Med2013 http://dx.doi.org/10.1016/j.mam.2013.08.003
   Web of Science ®Google Scholar
• PeacockCDWatkinsDNCancer stem cells and the ontogeny of lung cancerJ Clin Oncol200826172883288918539968
   PubMed Web of Science ®Google Scholar
• CarneyDNGazdarAFBunnPAJrGuccionJGDemonstration of the stem cell nature of clonogenic tumor cells from lung cancer patientsStem Cells1982131491646294885
   PubMedGoogle Scholar
• RawlinsELHoganBLEpithelial stem cells of the lung: privileged few or opportunities for many?Development2006133132455246516735479
   PubMed Web of Science ®Google Scholar
• KimCFJacksonELWoolfendenAEIdentification of bronchioalveolar stem cells in normal lung and lung cancerCell2005121682383515960971
   PubMed Web of Science ®Google Scholar
• GiangrecoAArwertENRosewellIRSnyderJWattFMStrippBRStem cells are dispensable for lung homeostasis but restore airways after injuryProc Natl Acad Sci USA2009106239286929119478060
   PubMed Web of Science ®Google Scholar
• LinCSongHHuangCAlveolar type II cells possess the capability of initiating lung tumor developmentPLoS ONE2012712e5381723285300
   PubMed Web of Science ®Google Scholar
• ShienKToyookaSYamamotoHAcquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cellsCancer Res201373103051306123542356
   PubMed Web of Science ®Google Scholar
• Corominas-FajaBOliveras-FerrarosCCuyàsEStem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibininCell Cycle201312213390340424047698
   PubMed Web of Science ®Google Scholar
• HoeijmakersJHGenome maintenance mechanisms for preventing cancerNature2001411683536637411357144
   PubMed Web of Science ®Google Scholar
• BirkbakNJEklundACLiQParadoxical relationship between chromosomal instability and survival outcome in cancerCancer Res201171103447345221270108
   PubMed Web of Science ®Google Scholar
• LeeAJEndesfelderDRowanAJChromosomal instability confers intrinsic multidrug resistanceCancer Res20117151858187021363922
   PubMed Web of Science ®Google Scholar
• SotilloRSchvartzmanJMSocciNDBenezraRMad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawalNature2010464728743644020173739
   PubMed Web of Science ®Google Scholar
• AlexandrovLBNik-ZainalSWedgeDCAustralian Pancreatic Cancer Genome InitiativeICGC Breast Cancer Consortium; ICGC MMML-Seq ConsortiumICGC PedBrainSignatures of mutational processes in human cancerNature2013500746341542123945592
   PubMed Web of Science ®Google Scholar
• KimSCJungYParkJA high-dimensional, deep-sequencing study of lung adenocarcinoma in female never-smokersPLoS ONE201382e5559623405175
   PubMed Web of Science ®Google Scholar
• SteadLFEganPDeveryAAn integrated inspection of the somatic mutations in a lung squamous cell carcinoma using next-generation sequencingPLoS ONE2013811e7882324244370
   PubMed Web of Science ®Google Scholar
• BalgkouranidouILiloglouTLianidouESLung cancer epigenetics: emerging biomarkersBiomarkers Med2013714958
   PubMed Web of Science ®Google Scholar
• LiuSVFabbriMGitlitzBJLaird-OffringaIAEpigenetic therapy in lung cancerFront Oncol2013313523755372
   PubMedGoogle Scholar
• RothschildSIEpigenetic Therapy in Lung Cancer – Role of microRNAsFront Oncol2013315823802096
   PubMedGoogle Scholar
• LundAHvan LohuizenMEpigenetics and cancerGenes Dev200418192315233515466484
   PubMed Web of Science ®Google Scholar
• DaskalosANikolaidisGXinarianosGHypomethylation of retrotransposable elements correlates with genomic instability in non-small cell lung cancerInt J Cancer20091241818718823011
   PubMed Web of Science ®Google Scholar
• DaskalosALogothetiSMarkopoulouSGlobal DNA hypomethylation-induced ΔNp73 transcriptional activation in non-small cell lung cancerCancer Lett20113001798620926182
   PubMed Web of Science ®Google Scholar
• HansenKDTimpWBravoHCIncreased methylation variation in epigenetic domains across cancer typesNat Genet201143876877521706001
   PubMed Web of Science ®Google Scholar
• BarlésiFGiacconeGGallegos-RuizMIGlobal histone modifications predict prognosis of resected non small-cell lung cancerJ Clin Oncol200725284358436417906200
   PubMed Web of Science ®Google Scholar
• SongJSKimYSKimDKParkSIJangSJGlobal histone modification pattern associated with recurrence and disease-free survival in non-small cell lung cancer patientsPathol Int201262318219022360506
   PubMed Web of Science ®Google Scholar
• JunttilaMRde SauvageFJInfluence of tumour micro-environment heterogeneity on therapeutic responseNature2013501746734635424048067
   PubMed Web of Science ®Google Scholar
• TrédanOGalmariniCMPatelKTannockIFDrug resistance and the solid tumor microenvironmentJ Natl Cancer Inst200799191441145417895480
   PubMed Web of Science ®Google Scholar
• MeadsMBGatenbyRADaltonWSEnvironment-mediated drug resistance: a major contributor to minimal residual diseaseNat Rev Cancer20099966567419693095
   PubMed Web of Science ®Google Scholar
• NakamuraTMatsumotoKKiritoshiATanoYNakamuraTInduction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactionsCancer Res19975715330533139242465
   PubMed Web of Science ®Google Scholar
• YamadaTMatsumotoKWangWHepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancerClin Cancer Res201016117418320008840
   PubMed Web of Science ®Google Scholar
• YamadaTTakeuchiSKitaKHepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancerJ Thorac Oncol20127227228022089117
   PubMed Web of Science ®Google Scholar
• SiegfriedJMWeissfeldLASingh-KawPWeyantRJTestaJRLandreneauRJAssociation of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancerCancer Res19975734334399012470
   PubMed Web of Science ®Google Scholar
• MeertAPPaesmansMMartinBThe role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysisBr J Cancer200287769470112232748
   PubMed Web of Science ®Google Scholar
• HegdePSJubbAMChenDPredictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumabClin Cancer Res201319492993723169435
   PubMed Web of Science ®Google Scholar
• Van der VeldtAALubberinkMBahceIRapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugsCancer Cell2012211829122264790
   PubMed Web of Science ®Google Scholar
• PaoWChmieleckiJRational, biologically based treatment of EGFR-mutant non-small-cell lung cancerNat Rev Cancer2010101176077420966921
   PubMed Web of Science ®Google Scholar
• PaoWGirardNNew driver mutations in non-small-cell lung cancerLancet Oncol201112217518021277552
   PubMed Web of Science ®Google Scholar
• StellaGMLuisettiMPozziEComoglioPMOncogenes in non-small-cell lung cancer: emerging connections and novel therapeutic dynamicsThe lancet. Respir Med201313251261
   PubMed Web of Science ®Google Scholar
• YuHAArcilaMERekhtmanNAnalysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancersClin Cancer Res20131982240224723470965
   PubMed Web of Science ®Google Scholar
• JännePAEngelmanJAJohnsonBEEpidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biologyJ Clin Oncol200523143227323415886310
   PubMed Web of Science ®Google Scholar
• MarchettiAMartellaCFelicioniLEGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatmentJ Clin Oncol200523485786515681531
   PubMed Web of Science ®Google Scholar
• KosakaTYatabeYEndohHKuwanoHTakahashiTMitsudomiTMutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implicationsCancer Res200464248919892315604253
   PubMed Web of Science ®Google Scholar
• GarassinoMCMartelliOBrogginiMTAILOR trialistsErlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trialLancet Oncol2013141098198823883922
   PubMed Web of Science ®Google Scholar
• BroseMSVolpePFeldmanMBRAF and RAS mutations in human lung cancer and melanomaCancer Res200262236997700012460918
   PubMed Web of Science ®Google Scholar
• EberhardDAJohnsonBEAmlerLCMutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinibJ Clin Oncol200523255900590916043828
   PubMed Web of Science ®Google Scholar
• PratilasCAHanrahanAJHalilovicEGenetic predictors of MEK dependence in non-small cell lung cancerCancer Res200868229375938319010912
   PubMed Web of Science ®Google Scholar
• SodaMChoiYLEnomotoMIdentification of the transforming EML4-ALK fusion gene in non-small-cell lung cancerNature2007448715356156617625570
   PubMed Web of Science ®Google Scholar
• ShawATYeapBYSolomonBJEffect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisLancet Oncol201112111004101221933749
   PubMed Web of Science ®Google Scholar
• ShawATYeapBYMino-KenudsonMClinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALKJ Clin Oncol200927264247425319667264
   PubMed Web of Science ®Google Scholar
• JankuFStewartDJKurzrockRTargeted therapy in non-small-cell lung cancer – is it becoming a reality?Nat Rev Clin Oncol20107740141420551945
   PubMed Web of Science ®Google Scholar
• LorussoVSilvestrisNMarechITORCH study: how much longer should we continue to use erlotinib in unselected patients with non-small-cell lung cancer?J Clin Oncol201331228828923233717
   PubMed Web of Science ®Google Scholar
• LiTKungHJMackPCGandaraDRGenotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapiesJ Clin Oncol20133181039104923401433
   PubMed Web of Science ®Google Scholar
• MogiAKuwanoHTP53 mutations in nonsmall cell lung cancerJ Biomed Biotechnol2011201158392921331359
   PubMedGoogle Scholar
• PanYZhangYLiYALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic featuresLung Cancer201484212112624629636
   PubMed Web of Science ®Google Scholar
• SequistLVHeistRSShawATImplementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practiceAnn Oncol201122122616262422071650
   PubMed Web of Science ®Google Scholar
• MitsudomiTYatabeYEpidermal growth factor receptor in relation to tumor development: EGFR gene and cancerFEBS J2010277230130819922469
   PubMed Web of Science ®Google Scholar
• YehPChenHAndrewsJNaserRPaoWHornLDNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapyClin Cancer Res20131971894190123344264
   PubMed Web of Science ®Google Scholar
• SharmaSVBellDWSettlemanJHaberDAEpidermal growth factor receptor mutations in lung cancerNat Rev Cancer20077316918117318210
   PubMed Web of Science ®Google Scholar
• WuJYYuCJChangYCYangCHShihJYYangPCEffectiveness of tyrosine kinase inhibitors on “uncommon” epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancerClin Cancer Res201117113812382121531810
   PubMed Web of Science ®Google Scholar
• MulloyRFerrandAKimYEpidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinibCancer Res20076752325233017332364
   PubMed Web of Science ®Google Scholar
• CareyKDGartonAJRomeroMSKinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinibCancer Res200666168163817116912195
   PubMed Web of Science ®Google Scholar
• YasudaHKobayashiSCostaDBEGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implicationsLancet Oncol2012131e23e3121764376
   PubMed Web of Science ®Google Scholar
• WuJYWuSGYangCHLung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment responseClin Cancer Res200814154877488218676761
   PubMed Web of Science ®Google Scholar
• GreulichHChenTHFengWOncogenic transformation by inhibitor-sensitive and -resistant EGFR mutantsPLoS Med2005211e31316187797
   PubMed Web of Science ®Google Scholar
• RielyGJPaoWPhamDClinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinibClin Cancer Res2006123 Pt 183984416467097
   PubMed Web of Science ®Google Scholar
• DengJShimamuraTPereraSProapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrionCancer Res20076724118671187518089817
   PubMed Web of Science ®Google Scholar
• GongYSomwarRPolitiKInduction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomasPLoS Med2007410e29417927446
   PubMed Web of Science ®Google Scholar
• CraggMSKurodaJPuthalakathHHuangDCStrasserAGefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimeticsPLoS Med20074101681168917973573
   PubMed Web of Science ®Google Scholar
• FaberACCorcoranRBEbiHBIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitorsCancer Discov20111435236522145099
   PubMed Web of Science ®Google Scholar
• NgKPHillmerAMChuahCTA common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancerNat Med201218452152822426421
   PubMed Web of Science ®Google Scholar
• FaberACLiDSongYDifferential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibitionProc Natl Acad Sci USA200910646195031950819850869
   PubMed Web of Science ®Google Scholar
• SongLCoppolaDLivingstonSCressDHauraEBMcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cellsCancer Biol Ther20054326727615753661
   PubMed Web of Science ®Google Scholar
• CetinZOzbilimGErdoganALuleciGKarauzumSBEvaluation of PTEN and Mcl-1 expressions in NSCLC expressing wild-type or mutated EGFRMed Oncol201027385386019763916
   PubMed Web of Science ®Google Scholar
• EngelmanJAMukoharaTZejnullahuKAllelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancerJ Clin Invest2006116102695270616906227
   PubMed Web of Science ®Google Scholar
• KawanoOSasakiHEndoKPIK3CA mutation status in Japanese lung cancer patientsLung Cancer200654220921516930767
   PubMed Web of Science ®Google Scholar
• GerlingerMRowanAJHorswellSIntratumor heterogeneity and branched evolution revealed by multiregion sequencingN Engl J Med20123661088389222397650
   PubMed Web of Science ®Google Scholar
• CrouchECStoneKRBlochMMcDivittRWHeterogeneity in the production of collagens and fibronectin by morphologically distinct clones of a human tumor cell line: evidence for intratumoral diversity in matrix protein biosynthesisCancer Res19874722608660922822240
   PubMed Web of Science ®Google Scholar
• BlackhallFHPintilieMWigleDAStability and heterogeneity of expression profiles in lung cancer specimens harvested following surgical resectionNeoplasia20046676176715720802
   PubMed Web of Science ®Google Scholar
• InukaiMToyookaSItoSPresence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancerCancer Res200666167854785816912157
   PubMed Web of Science ®Google Scholar
• SequistLVMartinsRGSpigelDFirst-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutationsJ Clin Oncol200826152442244918458038
   PubMed Web of Science ®Google Scholar
• TurkeABZejnullahuKWuYLPreexistence and clonal selection of MET amplification in EGFR mutant NSCLCCancer Cell2010171778820129249
   PubMed Web of Science ®Google Scholar
• BaiHWangZWangYDetection and clinical significance of intratumoral EGFR mutational heterogeneity in Chinese patients with advanced non-small cell lung cancerPLoS ONE201382e5417023418425
   PubMed Web of Science ®Google Scholar
• TaniguchiKOkamiJKodamaKHigashiyamaMKatoKIntratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinibCancer Sci200899592993518325048
   PubMed Web of Science ®Google Scholar
• GowCHChangYLHsuYCComparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancerAnn Oncol200920469670219088172
   PubMed Web of Science ®Google Scholar
• KalikakiAKoutsopoulosATrypakiMComparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLCBr J Cancer200899692392919238633
   PubMed Web of Science ®Google Scholar
• YatabeYMatsuoKMitsudomiTHeterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinomaJ Clin Oncol201129222972297721730270
   PubMed Web of Science ®Google Scholar
• MatsumotoSTakahashiKIwakawaRFrequent EGFR mutations in brain metastases of lung adenocarcinomaInt J Cancer200611961491149416642476
   PubMed Web of Science ®Google Scholar
• NagaiYMiyazawaHHuqunGenetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clampCancer Res200565167276728216105816
   PubMed Web of Science ®Google Scholar
• KamilaWKMichałSPawełKEGFR activating mutations detected by different PCR techniques in Caucasian NSCLC patients with CNS metastases: short reportClin Exp Metastasis20133081063107123892415
   PubMed Web of Science ®Google Scholar
• JiangSXYamashitaKYamamotoMEGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistanceInt J Cancer2008123112480248618785203
   PubMed Web of Science ®Google Scholar
• ArcilaMEOxnardGRNafaKRebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assayClin Cancer Res20111751169118021248300
   PubMed Web of Science ®Google Scholar
• TaniguchiKUchidaJNishinoKQuantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomasClin Cancer Res201117247808781521976538
   PubMed Web of Science ®Google Scholar
• KleinCASelection and adaptation during metastatic cancer progressionNature2013501746736537224048069
   PubMed Web of Science ®Google Scholar
• SequistLVWaltmanBADias-SantagataDGenotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitorsSci Transl Med201137575ra26
   PubMed Web of Science ®Google Scholar
• ThatcherNChangAParikhPGefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)Lancet200536694961527153716257339
   PubMed Web of Science ®Google Scholar
• BaiHWangZChenKInfluence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancerJ Clin Oncol201230253077308322826274
   PubMed Web of Science ®Google Scholar
• Jair BarDURoni Borshtein, Hovav Nechushtan, Amir Onn. EGFR mutation in lung cancer: tumor heterogeneity and the impact of chemotherapyChin Clin Oncol20132113
   Google Scholar
• De PasTPelosiGde BraudFModulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rareJ Clin Oncol200422244966497015611511
   PubMed Web of Science ®Google Scholar
• ChinTMQuinlanMPSinghAReduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatmentClin Cancer Res200814216867687618980981
   PubMed Web of Science ®Google Scholar
• PaoWMillerVAPolitiKAAcquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domainPLoS Med200523e7315737014
   PubMed Web of Science ®Google Scholar
• KobayashiSBoggonTJDayaramTEGFR mutation and resistance of non-small-cell lung cancer to gefitinibN Engl J Med2005352878679215728811
   PubMed Web of Science ®Google Scholar
• YunCHMengwasserKETomsAVThe T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATPProc Natl Acad Sci USA200810562070207518227510
   PubMed Web of Science ®Google Scholar
• CostaDBSchumerSTTenenDGKobayashiSDifferential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutationsJ Clin Oncol20082671182118418309959
   PubMed Web of Science ®Google Scholar
• BalakMNGongYRielyGJNovel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitorsClin Cancer Res200612216494650117085664
   PubMed Web of Science ®Google Scholar
• BeanJRielyGJBalakMAcquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinomaClin Cancer Res200814227519752519010870
   PubMed Web of Science ®Google Scholar
• CostaDBHalmosBKumarABIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutationsPLoS Med20074101669167917973572
   PubMed Web of Science ®Google Scholar
• TokumoMToyookaSIchiharaSDouble mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancerLung Cancer200653111712116730855
   PubMed Web of Science ®Google Scholar
• JackmanDMHolmesAJLindemanNResponse and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinibJ Clin Oncol200624274517452016983123
   PubMed Web of Science ®Google Scholar
• ClarkeJLPaoWWuNMillerVALassmanABHigh dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancerJ Neurooncol201099228328620146086
   PubMed Web of Science ®Google Scholar
• RielyGJKrisMGZhaoBProspective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimusClin Cancer Res200713175150515517785570
   PubMed Web of Science ®Google Scholar
• KurataTTamuraKKanedaHEffect of re-treatment with gefitinib (‘Iressa’, ZD1839) after acquisition of resistanceAnn Oncol200415117317414679138
   PubMed Web of Science ®Google Scholar
• EngelmanJAZejnullahuKMitsudomiTMET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signalingScience200731658271039104317463250
   PubMed Web of Science ®Google Scholar
• TakezawaKPirazzoliVArcilaMEHER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutationCancer Discov201221092293322956644
   PubMed Web of Science ®Google Scholar
• BarrSThomsonSBuckEBypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitionsClin Exp Metastasis200825668569318236164
   PubMed Web of Science ®Google Scholar
• UramotoHIwataTOnitsukaTShimokawaHHanagiriTOyamaTEpithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinomaAnticancer Res20103072513251720682976
   PubMed Web of Science ®Google Scholar
• ChungJHRhoJKXuXClinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIsLung Cancer201173217618221168239
   PubMed Web of Science ®Google Scholar
• WalterKHolcombTJanuarioTDNA methylation profiling defines clinically relevant biological subsets of non-small cell lung cancerClin Cancer Res20121882360237322261801
   PubMed Web of Science ®Google Scholar
• OgawaTLiggettTEMelnikovAAMethylation of death-associated protein kinase is associated with cetuximab and erlotinib resistanceCell Cycle20121181656166322487682
   PubMed Web of Science ®Google Scholar
• ZhuJWangYDuanJDNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancerJ Exp Clin Cancer Res20123118023009178
   PubMed Web of Science ®Google Scholar
• SalazarFMolinaMASanchez-RoncoMFirst-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patientsLung Cancer2011721849120705357
   PubMed Web of Science ®Google Scholar
• LiHHuHWangRPrimary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patientsOnco Targets Ther20143;7513524
   Web of Science ®Google Scholar
• YanoSWangWLiQHepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutationsCancer Res200868229479948719010923
   PubMed Web of Science ®Google Scholar
• YanoSYamadaTTakeuchiSHepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohortJ Thorac Oncol20116122011201722052230
   PubMed Web of Science ®Google Scholar
• MazièresJPetersSLepageBLung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectivesJ Clin Oncol201331161997200323610105
   PubMed Web of Science ®Google Scholar
• WangLHuHPanYPIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroupPLoS ONE201492e8829124533074
   PubMed Web of Science ®Google Scholar
• CheungHWDuJBoehmJSAmplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancersCancer Discov20111760862522586683
   PubMed Web of Science ®Google Scholar
• KimYHKweiKAGirardLGenomic and functional analysis identifies CRKL as an oncogene amplified in lung cancerOncogene201029101421143019966867
   PubMed Web of Science ®Google Scholar
• DanielsMGBowmanRVYangIAGovindanRFongKMAn emerging place for lung cancer genomics in 2013J Thorac Dis20135Suppl 5S491S49724163742
   PubMed Web of Science ®Google Scholar
• NavinNKendallJTrogeJTumour evolution inferred by single-cell sequencingNature20114727341909421399628
   PubMed Web of Science ®Google Scholar
• KorfBRRehmHLNew approaches to molecular diagnosisJAMA2013309141511152123571590
   PubMed Web of Science ®Google Scholar
• ImielinskiMBergerAHHammermanPSMapping the hallmarks of lung adenocarcinoma with massively parallel sequencingCell201215061107112022980975
   PubMed Web of Science ®Google Scholar
• Network CGARCancer Genome Atlas Research NetworkComprehensive genomic characterization of squamous cell lung cancersNature2012489741751952522960745
   PubMed Web of Science ®Google Scholar
• PotterNEErminiLPapaemmanuilESingle-cell mutational profiling and clonal phylogeny in cancerGenome Res201323122115212524056532
   PubMed Web of Science ®Google Scholar
• NavinNHicksJFuture medical applications of single-cell sequencing in cancerGenome Med2011353121631906
   PubMed Web of Science ®Google Scholar
• JakobsenJNSørensenJBIntratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancerCancer Chemother Pharmacol201269228929922130585
   PubMed Web of Science ®Google Scholar
• MurtazaMDawsonSJTsuiDWNon-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNANature2013497744710811223563269
   PubMed Web of Science ®Google Scholar
• AllardWJMateraJMillerMCTumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseasesClin Cancer Res200410206897690415501967
   PubMed Web of Science ®Google Scholar
• MaheswaranSSequistLVNagrathSDetection of mutations in EGFR in circulating lung-cancer cellsN Engl J Med2008359436637718596266
   PubMed Web of Science ®Google Scholar
• NiXZhuoMSuZReproducible copy number variation patterns among single circulating tumor cells of lung cancer patientsProc Natl Acad Sci USA201311052210832108824324171
   PubMed Web of Science ®Google Scholar
• KimuraHKasaharaKKawaishiMDetection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancerClin Cancer Res200612133915392116818687
   PubMed Web of Science ®Google Scholar
• GotoKIchinoseYOheYEpidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancerJ Thorac Oncol20127111512121900837
   PubMed Web of Science ®Google Scholar
• LiuXLuYZhuGThe diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologiesJ Clin Pathol201366121065106923888061
   PubMed Web of Science ®Google Scholar
• KuangYRogersAYeapBYNoninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancerClin Cancer Res20091582630263619351754
   PubMed Web of Science ®Google Scholar
• BearzattoAConteDFrattiniMp16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancerClin Cancer Res20028123782378712473590
   PubMed Web of Science ®Google Scholar
• HsuHSChenTPHungCHCharacterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasmaCancer200711092019202617876837
   PubMed Web of Science ®Google Scholar
• AnQLiuYGaoYDetection of p16 hypermethylation in circulating plasma DNA of non-small cell lung cancer patientsCancer Lett20021881–210911412406555
   PubMed Web of Science ®Google Scholar
• PorterJRStainsCISegalDJGhoshISplit beta-lactamase sensor for the sequence-specific detection of DNA methylationAnal Chem200779176702670817685552
   PubMed Web of Science ®Google Scholar
• PonomaryovaAARykovaEYCherdyntsevaNVPotentialities of aberrantly methylated circulating DNA for diagnostics and post-treatment follow-up of lung cancer patientsLung Cancer201381339740323806794
   PubMed Web of Science ®Google Scholar
• ShinYLabel-free methylation specific sensor based on silicon microring resonators for detection and quantification of DNA methylation biomarkers in bladder cancerSensors Actuators B: Chem2013177404411
   Web of Science ®Google Scholar
• RedovaMSanaJSlabyOCirculating miRNAs as new blood-based biomarkers for solid cancersFuture Oncol20139338740223469974
   PubMed Web of Science ®Google Scholar
• BoeriMVerriCConteDMicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancerProc Natl Acad Sci USA201110893713371821300873
   PubMed Web of Science ®Google Scholar
• HuZChenXZhaoYSerum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancerJ Clin Oncol201028101721172620194856
   PubMed Web of Science ®Google Scholar
• ZhangHSuYXuFKongJYuHQianBCirculating microRNAs in relation to EGFR status and survival of lung adenocarcinoma in female non-smokersPLoS ONE2013811e8140824282590
   PubMed Web of Science ®Google Scholar
• LiBRenSLiXMiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancerLung Cancer2013
   Web of Science ®Google Scholar
• VoliniaSCalinGALiuCGA microRNA expression signature of human solid tumors defines cancer gene targetsProc Natl Acad Sci USA200610372257226116461460
   PubMed Web of Science ®Google Scholar
• WangYZhengDTanQWangMXGuLQNanopore-based detection of circulating microRNAs in lung cancer patientsNat Nanotechnol201161066867421892163
   PubMed Web of Science ®Google Scholar
• TaguchiFSolomonBGregorcVMass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional studyJ Natl Cancer Inst2007991183884617551144
   PubMedGoogle Scholar
• ButtsCAVeriStrat validated in patients with non-small-cell lung cancerLancet Oncol201415767167224831978
   PubMed Web of Science ®Google Scholar
• GregorcVNovelloSLazzariCPredictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trialLancet Oncol201415771372124831979
   PubMed Web of Science ®Google Scholar
• AmannJMLeeJWRoderHGenetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503J Thorac Oncol20105216917820035238
   PubMed Web of Science ®Google Scholar
• CarboneDPDingKRoderHPrognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trialJ Thorac Oncol20127111653166023059783
   PubMed Web of Science ®Google Scholar
• StinchcombeTERoderJPetermanAHA retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancerJ Thorac Oncol20138444345123370367
   PubMed Web of Science ®Google Scholar
• LazzariCSpreaficoABachiAChanges in plasma mass-spectral profile in course of treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitorsJ Thorac Oncol201271404821964534
   PubMed Web of Science ®Google Scholar
• MilanELazzariCAnandSSAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitorsJ Proteomics201276Spec9110122771314
   PubMed Web of Science ®Google Scholar
• KwakELSordellaRBellDWIrreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinibProc Natl Acad Sci USA2005102217665767015897464
   PubMed Web of Science ®Google Scholar
• JiHZhaoXYuzaYEpidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitorsProc Natl Acad Sci USA2006103207817782216672372
   PubMed Web of Science ®Google Scholar
• LiDAmbrogioLShimamuraTBIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer modelsOncogene200827344702471118408761
   PubMed Web of Science ®Google Scholar
• KatakamiNAtagiSGotoKLUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or bothJ Clin Oncol201331273335334123816963
   PubMed Web of Science ®Google Scholar
• MillerVAHirshVCadranelJAfatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trialLancet Oncol201213552853822452896
   PubMed Web of Science ®Google Scholar
• SequistLVYangJCYamamotoNPhase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutationsJ Clin Oncol201331273327333423816960
   PubMed Web of Science ®Google Scholar
• WuYLZhouCHuCPAfatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trialLancet Oncol201415221322224439929
   PubMed Web of Science ®Google Scholar
• YangJCShihJYSuWCAfatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trialLancet Oncol201213553954822452895
   PubMed Web of Science ®Google Scholar
• RamalingamSSBlackhallFKrzakowskiMRandomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancerJ Clin Oncol201230273337334422753918
   PubMed Web of Science ®Google Scholar
• YangJCHirshVSchulerMSymptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutationsJ Clin Oncol201331273342335023816967
   PubMed Web of Science ®Google Scholar
• SequistLVBesseBLynchTJNeratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancerJ Clin Oncol201028183076308320479403
   PubMed Web of Science ®Google Scholar
• ZhouWErcanDChenLNovel mutant-selective EGFR kinase inhibitors against EGFR T790MNature200946272761070107420033049
   PubMed Web of Science ®Google Scholar
• NanjoSYamadaTNishiharaHAbility of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitorsPLoS ONE2013812e8470024386407
   PubMed Web of Science ®Google Scholar
• ReckampKLGiacconeGCamidgeDRA phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinibCancer201412081145115424501009
   PubMed Web of Science ®Google Scholar
• JännePAvon PawelJCohenRBMulticenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancerJ Clin Oncol200725253936394417761977
   PubMed Web of Science ®Google Scholar
• ChiapporiAAEllisPMHammJTA phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancerJ Thorac Oncol2006191010101917409987
   PubMed Web of Science ®Google Scholar
• XuLKikuchiEXuCCombined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and METCancer Res201272133302331122552292
   PubMed Web of Science ®Google Scholar
• ChenXZhouJYZhaoJChenJJMaSNZhouJYCrizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cellsAnticancer Drugs201324101039104623962905
   PubMed Web of Science ®Google Scholar
• NakagawaTTakeuchiSYamadaTCombined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancerMol Cancer Ther201211102149215722844075
   PubMed Web of Science ®Google Scholar
• GoldmanJWLauxIChaiFPhase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinibCancer2012118235903591122605616
   PubMed Web of Science ®Google Scholar
• RiceJWVealJMBarabaszATargeting of multiple signaling pathways by the Hsp90 inhibitor SNX-2112 in EGFR resistance models as a single agent or in combination with erlotinibOncol Res2009185–622924220225761
   PubMed Web of Science ®Google Scholar
• WangXSongXZhuoWThe regulatory mechanism of Hsp90alpha secretion and its function in tumor malignancyProc Natl Acad Sci USA200910650212882129319965370
   PubMed Web of Science ®Google Scholar
• ShimamuraTLowellAMEngelmanJAShapiroGIEpidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycinsCancer Res200565146401640816024644
   PubMed Web of Science ®Google Scholar
• UenoTTsukudaKToyookaSStrong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancerLung Cancer2012761263121996088
   PubMed Web of Science ®Google Scholar
• ShimamuraTLiDJiHHsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistanceCancer Res200868145827583818632637
   PubMed Web of Science ®Google Scholar
• SocinskiMAGoldmanJEl-HariryIA multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancerClin Cancer Res201319113068307723553849
   PubMed Web of Science ®Google Scholar
• GaronEBFinnRSHamidiHThe HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growthMol Cancer Ther201312689090023493311
   PubMed Web of Science ®Google Scholar
• FerraraNThe role of vascular endothelial growth factor in pathological angiogenesisBreast Cancer Res Treat19953621271378534862
   PubMed Web of Science ®Google Scholar
• SetoTHigashiyamaMFunaiHPrognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancerLung Cancer2006531919616697074
   PubMed Web of Science ®Google Scholar
• SandlerAGrayRPerryMCPaclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med2006355242542255017167137
   PubMed Web of Science ®Google Scholar
• RSO’NeillVJFehrenbacherLPhase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancerJ Clin Oncol200725304743475017909199
   PubMed Web of Science ®Google Scholar
• HerbstRSJohnsonDHMininbergEPhase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancerJ Clin Oncol200523112544255515753462
   PubMed Web of Science ®Google Scholar
• HerbstRSAnsariRBustinFEfficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trialLancet201137797801846185421621716
   PubMed Web of Science ®Google Scholar
• JohnsonBEKabbinavarFFehrenbacherLATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancerJ Clin Oncol201331313926393424101054
   PubMed Web of Science ®Google Scholar
• AkerleyWBoucherKRichNA phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluationLung Cancer201379330731123273522
   PubMed Web of Science ®Google Scholar
• SpigelDRBurrisHAIIIGrecoFARandomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancerJ Clin Oncol201129182582258921576636
   PubMed Web of Science ®Google Scholar
• RosellRBivonaTGKarachaliouNGenetics and biomarkers in personalisation of lung cancer treatmentLancet2013382989372073123972815
   PubMed Web of Science ®Google Scholar
• GaspariniGLongoRThe paradigm of personalized therapy in oncologyExpert Opin Ther Targets201216Suppl 1S7S1622073968
   PubMed Web of Science ®Google Scholar
• MaPCPersonalized targeted therapy in advanced non-small cell lung cancerCleve Clin J Med201279Electronic Suppl 1eS56eS6022614968
   PubMedGoogle Scholar